However, weight loss from weight cycling can reduce diabetes risk in people with obesity Weight cycling is associated with a higher risk of death, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Weight cycling, or the constant losing and gaining of weight (usually from diet), leads to adverse health outcomes....
As the prices of newer insulin formulations have soared, there may be a role for older formulations for patients who struggle with the cost. However, patients need education on how to safely and effectively use these cheaper options. The price of insulin has soared to such levels that it could be costing lives. Consider...
In its inaugural event, the Disrupt Diabetes Design Challenge brought together new perspectives to tackle persistent challenges diabetes with a human-first, design-centric approach. A mechanical engineer is sitting in a conference room at Stanford University. At the table, he is joined by an emergency medicine clinical pharmacist and healthcare designer. Across from them sit two...
Streamlined Method Helps People with Diabetes Act on CGM Data
Endocrine Society experts develop new approach to benefit users of different devices Endocrine Society experts have expanded their efforts to develop streamlined methods for continuous glucose monitor (CGM) users to better manage their blood sugar levels. A panel of diabetes experts created a method for users of Abbott FreeStyle Libre CGM systems, which are among...
Pump It Up: Diabetes Technologies Continue to Revolutionize Care
As devices become smarter and smarter and improve patient outcomes, they also pose challenges for patient and clinician education. While clinicians ensure all patients are up-to-speed on the new technology, a new threat looms: Keeping data safe. In an early episode of the CBS crime drama Elementary, a man is found dead of an apparent...
Treatment with empagliflozin may positively impact life expectancy in adults with type 2 diabetes and established cardiovascular disease, according to results from the EMPA-REG OUTCOME trial recently published in Circulation. Using actuarial methods and assuming that the demonstrated beneficial effects of empagliflozin remain consistent with long-term use, empagliflozin was estimated to extend life expectancy by one...
Teachable Moments: Using Journey Boards for Pediatric Diabetes Patients
When children are first diagnosed with type 1 diabetes, there are myriad challenges for the patient and the parents. A new educational program developed by Phoenix Children’s Hospital called Our Journey in the Hospital has proven to be an effective tool for the patients, parents, and clinical team. About 12 years ago at Phoenix Children’s...
The Phase 3 PANORAMA trial evaluating aflibercept injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its one-year (52-week) primary endpoint and key secondary endpoints, the drug’s manufacturer announced today. Regeneron Pharmaceuticals is marketing the drug as EYELA. On the primary endpoint at one year, 80% and 65% of patients receiving...
Diabetes Research Articles
Get the most up to date news on diabetes research and treatment. For more information read the latest issue of Endocrine News.
